Glucagon-like Peptide-1 Receptor PET/CT in GLP-1R Related Disease

Launched by TIANJIN MEDICAL UNIVERSITY · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a special imaging technique called PET/CT using a substance called Exendin 4 to help diagnose certain types of tumors related to GLP-1 receptor diseases, including insulinomas. The goal is to see how effective this imaging method is at identifying both primary tumors (the original site of cancer) and metastatic lesions (cancer that has spread to other areas). The researchers are looking for adult participants aged 18 and older who have suspected or newly diagnosed malignant tumors, and who are scheduled for an Exendin 4 PET/CT scan.

To participate, individuals must be able to give informed consent, meaning they understand the study and agree to join. However, people with non-cancerous lesions, those who are pregnant, or those unable to provide consent are not eligible. If you choose to participate, you can expect a PET/CT scan that will help researchers learn more about the effectiveness of this imaging technique in diagnosing GLP-1 receptor related diseases. This is an exciting opportunity to contribute to medical research that could improve diagnosis and treatment for future patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Exendin 4 PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.
• Exclusion Criteria:
• • - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.